TDD Industry News and Views: Weekly Updates on Comings, Goings, and Other Happenings in Dermatology
Sudo Biosciences Raises $116M Series B Financing to Advance TYK2 Therapeutics Programs Into the Clinic Sudo Biosciences raised $116 million Series B financing to advance two investigational TYK2 candidates into the clinic in 2024. Sudo is developing a potential first-in-class topical TYK2 inhibitor for psoriasis and other immune-mediated dermatologic diseases. In addition, Sudo’s CNS program is […]